The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2021 | Cytopenic MF: new approaches
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer, Houston, TX, discusses novel approaches to treating cytopenic myelofibrosis (MF). Dr Bose predominantly talks on the JAK2 inhibitor pacritinib, highlighting outcomes from the Phase III PERSIST-1 (NCT01773187) and PERSIST-2 (NCT02055781) trials. Dr Bose also talks on the ability of momelotinib, luspatercept, and pelabresib to ameliorate anemia. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Prithviraj Bose, MBBS, has received honoraria from Incyte, Celgene, BMS, CTI BioPharma, Sierra Oncology, Novartis, Blueprint Medicines and Kartos; and has received research support from Incyte, Celgene, BMS, CTI BioPharma, Constellation, Kartos, Blueprint Medicines, Astellas, Pfizer, Promedior and NS Pharma.
